---
title: Research on Translational Outcomes of Alcohol (Project RETRO)
nct_id: NCT04742348
overall_status: WITHDRAWN
phase: PHASE4
sponsor: University of Washington
study_type: INTERVENTIONAL
primary_condition: Alcohol Drinking
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04742348.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04742348"
ct_last_update_post_date: 2023-02-13
last_seen_at: "2026-05-12T06:44:31.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Research on Translational Outcomes of Alcohol (Project RETRO)

**NCT ID:** [NCT04742348](https://clinicaltrials.gov/study/NCT04742348)

## Key Facts

- **Status:** WITHDRAWN
- **Why Stopped:** COVID-19 and expiration of funding
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 0
- **Lead Sponsor:** University of Washington
- **Conditions:** Alcohol Drinking
- **Start Date:** 2023-02
- **Completion Date:** 2023-08
- **CT.gov Last Update:** 2023-02-13

## Brief Summary

The primary aim of the current study is to assess the effect of a single dose of carbidopa-levodopa on ad libitum alcohol consumption and alcohol craving in young adults with a history of binge drinking.

## Detailed Description

This is a small (N = 42) 2-arm, double-blind, randomized controlled pilot study to assess the effect of a single dose of immediate release carbidopa-levodopa (50mg/500mg) to acutely reduce alcohol consumption and craving in college students with a history of heavy episodic drinking. Participants will be between 21-24 years old from 2- and 4- year colleges in the Seattle Metropolitan area. Interested students will contact the study line and provide verbal consent to be sent a link to an online screening survey. Eligible participants will be scheduled to come in for the ad libitum alcohol administration. Participants will receive either the carbidopa-levodopa or a placebo and complete the alcohol administration protocol.

## Eligibility

- **Minimum age:** 21 Years
- **Maximum age:** 24 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Enrolled in 2- or 4-year college program
* Currently living in the Seattle Metropolitan area
* Have at least two or more episodes of heavy episodic drinking (4/5 or more drinks in a 2 hours for women/men) in the past 30 days.

Exclusion Criteria:

* Exclusion criteria include:
* past-month severe alcohol or other substance use disorders,
* mood or anxiety disorder
* suicidal ideation
* risk of psychotic disorders
* excessive alcohol use reaching a Blood Alcohol Level greater than .30%
* history of serious medical conditions, regular use of prescription psychotropic or pain medication
* history of negative reactions to alcohol
* history of treatment for alcohol use disorder
* pregnancy or nursing.
* use of non-selective monoamine oxidase inhibitors in the past 2 weeks.
* narrow-angle glaucoma
* undiagnosed skin lesions,
* have a history of melanoma, cardiac issues or peptic ulcer.
* Currently taking or prescribed any form of levodopa or D2 agonists, D2 antagonists, isoniazid, methylphenidate, bupropion, Viagra, or phosphodiesterase inhibitors.
```

## Arms

- **Control, Placebo** (PLACEBO_COMPARATOR) — Similar looking tablet(s) to active drug will be administered in a single dose to those who are randomly assigned to this group.
- **Active Drug, Carbidopa + Levodopa** (EXPERIMENTAL) — Single dose of immediate release carbidopa-levodopa (50mg/500mg).

## Interventions

- **Carbidopa Levodopa** (DRUG) — Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
- **Placebo** (DRUG) — Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.

## Primary Outcomes

- **Alcohol Consumption** _(time frame: 1 hour)_ — Number of alcoholic drinks consumed
- **Alcohol Craving** _(time frame: 30 minutes in to alcohol administration)_ — Amount of alcohol craving as assessed by the Alcohol Urge Questionnaire by Bohn, Krahn \& Staehler (1995)

## Secondary Outcomes

- **Alcohol craving** _(time frame: At the end of alcohol administration. Alcohol administration is 1 hour.)_

## Recent Field Changes (last 30 days)

- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04742348.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04742348*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*